Upsher-Smith
As of the edition of 20 October 2026, Upsher-Smith runs 7 drugs, 7 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 7 |
| Total | 7 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Acetaminophen | none listed | 17 |
| Estradiol | Ends 2032 (patent) | 6 |
| Testosterone | none listed | 4 |
| Topiramate | none listed | 25 |
| Potassium chloride | none listed | 0 |
| Calcitonin salmon | none listed | 1 |
| Potassium | none listed | 0 |
A route B row is one company at one target.